PT - JOURNAL ARTICLE AU - NORIHIKO YAMAMOTO AU - KAZUMOTO MURATA AU - HIROYUKI FUKE AU - TOMOKO INOUE AU - YUTAKA YAMANAKA AU - YUKIKO SAITOU AU - KEIICHI ITO AU - KAZUSHI SUGIMOTO AU - MUTSUMI KOYAMA AU - KATSUYA SHIRAKI AU - TAKESHI NAKANO TI - Macrocytic Anemia during Low-dose Cisplatin and 5-Fluorouracil through Implanted Infusion Port for Unresectable Hepatobilliary Malignancies DP - 2005 Mar 01 TA - Anticancer Research PG - 1243--1246 VI - 25 IP - 2B 4099 - http://ar.iiarjournals.org/content/25/2B/1243.short 4100 - http://ar.iiarjournals.org/content/25/2B/1243.full SO - Anticancer Res2005 Mar 01; 25 AB - The efficacy of continuous arterial infusion chemotherapy through a subcutaneously implanted port has been reported with less adverse effects than systemic chemotherapy in hepatobilliary malignancies. However, macrocytic anemia is sometimes seen during this therapy. In 25 patients (22 with hepatocellular carcinoma, 3 with cholangiocellular carcinoma) treated with cisplatinum (10mg/day) and 5-Fluorouracil (5-FU) (250 mg/day), the frequency of anemia and its etiologies were evaluated. Moreover, the two groups (“anemia” and “no anemia” group) were compared with their backgrounds. Nine cases (36%) showed macrocytic anemia without any evident etiologies during therapy. The cumulative appearance rate of anemia was 19% at 12 weeks and 51% at 18 weeks. The Child-Pugh score or Japanese integrated staging (JIS) score were significantly higher in the “anemia” group than that in the “no anemia” group. Conclusion: Attention should be paid to slow progressive macrocytic anemia during low-dose cisplatinum and 5-FU, especially in patients with advanced liver cirrhosis. Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved